Upstream Bio, Inc.
UPB Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.75
KIRA · Stoqly’s AI analyst, in plain words
- Upstream Bio, Inc. had $2.9M of revenue in fiscal 2025, up 20.4% on the year before.
- Its operating margin was −5,618.8%, down 2,337.6 pts: of every 100 in sales, about −5,619 is left after running the business.
- Upstream Bio, Inc. lost $143M in fiscal 2025.
- Free cash flow was −$133M in fiscal 2025, −4,675.5% of revenue.
Market cap
$150M
P/E
—
Revenue
$2.9M
Net income
−$143M
Free cash flow
−$133M
Operating margin
−5,618.8%
Upstream Bio, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+20.4%
Yes. Sales grew 20.4% last year.
Does it make a profit?
−5,026.0%
No. It lost money last year.
Does profit turn into cash?
−4,675.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Upstream Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Upstream Bio, Inc.
- CIK
- 0002022626
Upstream Bio, Inc. · UPB
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $2.4M | $2.4M | $2.9M |
| Revenue growth | — | −0.4% | 20.4% |
| Operating margin | −1,685.5% | −3,281.2% | −5,618.8% |
| Net income | −$20.5M | −$62.8M | −$143M |
| Net margin | −862.9% | −2,650.0% | −5,026.0% |
| Diluted EPS | −$12.95 | −$5.58 | −$2.66 |
| Cash | |||
| Cash from operations | −$37.9M | −$59.2M | −$133M |
| Capital expenditure | $0.1M | $0.5M | $0.2M |
| Free cash flow | −$38.1M | −$59.7M | −$133M |
| FCF margin | −1,599.6% | −2,518.3% | −4,675.5% |
| Share count change | — | 363.2% | 293.6% |
| Debt and strength | |||
| Cash and short-term investments | $110M | $470M | $342M |
| Shareholders' equity | −$123M | $470M | $340M |
| Current ratio | 18.0x | 44.6x | 26.2x |
| Returns and quality | |||
| Return on equity | — | −36.2% | −35.4% |
| Return on tangible equity | — | −16.3% | −42.2% |
| Piotroski F-score | — | 3 | 2 |
| Altman Z'' | −13.4 | 45.6 | 25.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.1M
5 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Upstream Bio, Inc. · UPB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.75 a share, the company is worth $150M.
Source: SEC EDGAR XBRL filings (CIK 0002022626). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.